Scorpion Therapeutics was founded to broaden the reach and impact of precision medicine to more people with cancer. The company is integrating cutting-edge technologies across target discovery, medicinal chemistry, and translational medicine to deliver Precision Oncology 2.0. Scorpion's experienced leadership team is executing a fit-to-purpose model to efficiently unlock the next generation of precision oncology.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/26/20 | $108,000,000 | Series A |
Abingworth Atlas Venture  Omega Funds Partners HealthCare Innovation Vida Ventures | undisclosed |
| 08/04/24 | $150,000,000 | Series C |
Abingworth Atlas Venture Boxer Capital EcoR1 Capital Fidelity Management & Research Company Frazier Life Sciences Invus Lightstone Ventures Logos Capital Nextech Invest Omega Funds OrbiMed Advisors Surveyor Capital Vida Ventures Wellington Management Willett Advisors Woodline Partners | undisclosed |
